Role of pregabalin in the treatment of generalized anxiety disorder

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 2, 2007, Pages 185-191

  Baldwin, David S ^a,b,c   Ajel, Khalil ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Generalized anxiety disorder; Pregabalin; Telerability

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; GLUTAMIC ACID; HYDROXYZINE; LORAZEPAM; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PAROXETINE; PLACEBO; PREGABALIN; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUBSTANCE P; TRIFLUOPERAZINE; VENLAFAXINE; VOLTAGE GATED CALCIUM CHANNEL;

ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR THERAPY; BLOOD PRESSURE; BREATHING RATE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DIAGNOSTIC VALUE; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; FOOD; FOOD DRUG INTERACTION; GENERALIZED ANXIETY DISORDER; HEART RATE; HUMAN; INSOMNIA; LONG TERM CARE; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOTHERAPY; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 34249893069     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.2.185     Document Type: Article

References (42)

1. Abelson JL, Glitz D, Cameron OG, et al. 1991. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry, 48:157-62.
2. Allgulander C, Florea I, Huusom AKT. 2006. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol, 9:495-505.
3. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text revision (DSM-IV-TR™). Washington: American Psychiatric Association, p 472-6.
4. Baldwin DS Anderson IM, Nutt DJ, et al. 2005. Evidence-based guidelines for the pharmacological treatment of anxiety disorders:recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 19:567-96.
5. Baldwin DS, Polkinghorn C. 2005. Evidence-based pharmacotherapy of generalised anxiety disorder. Int J Neuropsychopharmacol, 8:293-302.
6. Baldwin DS, Huusom AKT, Maehlum E. 2006. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, placebo-controlled, double-blind study. Br J Psychiatry, 189:264-72.
7. Bandelow B, Zohar J, Hollander E, et al. 2002. World Federation of Socieities of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumautic Stress disorders. World J Biol Psychiatry, 3:171-199.
8. Bielski RJ, Bose A, Chang C-G. 2005. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry, 17:65-9.
9. Brawman-Mintzer O, Knapp RG, Nietert PJ. 2005. Adjunctive risper done in generalized anxiety disorder:a double-blind, placebo-controlled study. J Clin Psychiatry, 66:1321-5.
10. Feltner DE, Crockatt JG, Dobovsky SJ, et al. 2003. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol, 23:240-9.
11. Germine M, Goddard AW, Woods SW et al. 1992. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry, 32:457-61.
12. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol, 32:50-5.
13. Hamilton, M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatr, 23:56-62.
14. Hindmarch I, Dawson J, Stanley N. 2002. Evaluation of the cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers [abstract]. Int J Neuropsychopharmacol, 5:1-241.
15. Hindmarch I, Dawson J, Stanley N. 2005. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep, 28:187-93.
16. Montgomery SA, Tobias K, Zornberg GL, et al. 2006. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder:a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry, 67:771-82.
17. Kavoussi R. 2006. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol, 16(Suppl 2):S128-33.
18. Kendler KS, Neale MC, Kessler RC et al. 1992. Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry, 49:716-22.
19. Kessler RC, DuPont RL, Berglund et al. 1999. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry, 156:1915-23.
20. Khan A, Farfel GM, Brock JD et al. 2006. Efficacy and safety of pregabalin for the treatment of GAD in elderly patients [abstract]. 159th Annual Meeting of the American Psychiatric Association. 2006 May 20-25; Toronto, Canada: NR681. 283-4.
21. Lieb R, Becker E, Altamura C. 2005. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol, 15:445-52.
22. Lydiard B, Bielski RJ, Tobias K et al. 2003. The efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) [abstract]. Eur Neuropsychopharmacol, 13(Suppl 4):S377 (p 3.055).
23. Mitte K, Noack P, Steil R et al. 2005. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol, 25:141-50.
24. Mogg K, Bradley BP, Millar N et al. 1995. A follow-up study of cognitive bias in generalised anxiety disorder. Behav Res Ther, 33:927-35.
25. Mogg K, Baldwin DS, Brodrick P et al. 2004. Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacol (Berl), 176:466-70.
26. Montgomery SA, Rickels K, Zornberg GL et al. 2003. Pregabalin in generalized anxiety disorder:speed of onset [abstract]. Eur Neuropsychopharmacol, 13(Suppl 4):S376 (p 3.054).
27. Montgomery SA, Sheehan DV, Meoni P. 2002. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res, 36:209-17.
28. Ormel J, Van Den Brink W, Koeter MW et al. 1990. Recognition, management and outcome of psychological disorders in primary care: a naturalistic follow-up study. Psychol Med, 20:909-23.
29. Pande AC, Crockatt MA, Janney C et al. 2006. Pregabalin treatment of GAD. Presented at: American Psychiatric Association 153rd Annual Meeting. 2006 May 13-18; Chicago, IL. (Abstract NR244). Accessed 15 Feb 2006. URL: http://wwwpsych.org/edu/other_res/lib_archives/meetings/ 2000nra.pdf.
30. Pande AC, Crockatt JG, Feltner DE et al. 2003. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry, 160:533-40.
31. Pfizer Ltd. 2006. Summary of Product Characteristics. Lyrica (pregabalin). May 2006.
32. Pohl RB, Feltner DE, Fieve RR et al. 2005. Efficacy of pregabalin in the treatment of generalized anxiety disorder:double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol, 25:151-8.
33. Pollack MH, Simon NM, Zalta AK et al. 2006. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder:a placebo controlled study. Biol Psychiatry, Feb 1, 59:211-5 [Epub ahead of print].
34. Randinitis EJ, Posvar EL, Alvey CW et al. 2003. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol, 43:277-83.
35. Rickels K, Pollack MH, Feltner DE et al. 2005. Pregabalin for treatment of generalized anxiety disorder:a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry, 62:1022-30.
36. Smith W, Targum S, Feltner DE et al. 2002. Pregabalin in generalized anxiety disorder:long term efficacy and relapse prevention [abstract]. Eur Neuropsychopharmacol, 12(Suppl 3):S350 (p 3.047).
37. Stahl SM. 2004. Anticonvulsants as anxiolytics: Part 2. Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry, 65:460-1.
38. Stocchi FG, Nordera G, Jokinen RH. 2003. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry, 64:250-8.
39. 2-proteins: Pfizer Satellite Symposium to the 2003 Society for Neuroscience meeting. 2003 November 10; Sheraton New Orleans Hotel, New Orleans, LA. CNS Drug Rev, 10:183-8.
40. Tiihonen J, Kuikka J, Rasanen P et al. 1997. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder:a fractional analysis. Mol Psychiatry, 2:463-71.
41. Wittchen HU, Kessler RC, Beesdo K et al. 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry, 63(Suppl 8):24-34.
42. [WHO] World Health Organization. 1994. Pocket Guide to the ICD-10 Classification of Mental and Behavioural Disorders with Glossary and Diagnostic Criteria for Research (DCR-10). Geneva: World Health Organization. Edinburgh: Churchill Livingstone, p 158-60.